Abivax Secures $920 Million to Push U. S. Launch of Bowel Disease Drug

Abivax, the French biotech company developing a bowel disease treatment, has raised $920 million in fresh capital. The infusion will sustain operations through the end of 2029 and fund a U.S. launch of its flagship drug, obefazimod.

Key Highlights

• Runway to 2029 – The new cash reserves provide a long‑term safety net for research, development, and commercialization.
• U.S. Expansion – Infrastructure will be built to support the launch of obefazimod in America.
• Operational Funding – Proceeds cover operating costs and commercial activities for the next decade.
• No Need for External Partner – The company can avoid a partnership with a large pharma, reinforcing its independence.
• Offensive Cash Strategy – CEO emphasizes strong reserves as a proactive stance.

Recent Market Dynamics

• Last Week’s IPO Activity – Underwriters exercised their full option to purchase additional American depository shares.
• Volatility Recap – Earlier this month, a late‑stage trial reported cancer cases. Shares fell sharply but recovered once malignancy rates aligned with expectations.
• Share Performance – Despite volatility, shares have surged over 1,600 % in the past year.

Potential Valuation & Interest

• Analysts project a sale could reach $23 billion, attracting large pharma with immunology and inflammation portfolios.
• The Paris listing continues to attract investors, buoyed by recent efficacy data.

Outlook

Abivax is positioned to leverage its progress independently, with a robust financial foundation and a clear path toward U.S. market entry.